3 Resilient Defense Stocks to Buy Now

The FY2027 Department of War budget request totals $1.45T, up $440.9B (+44%) vs FY2026 enacted, with NATO aiming for 5% of GDP by 2035—bolstering multi-year defense demand. Lockheed reaffirmed FY2026 EPS of $29.35–$30.25 (FCF $6.50B–$6.80B) but saw Q1 EPS miss ($6.44 vs $6.70) and negative Q1 FCF of -$291M; Northrop beat Q1 adjusted EPS ($6.14 vs $6.06) and raised FY2026 sales to $43.5B–$44.0B with backlog at $95.6B, despite Q1 FCF of -$1.82B. RTX delivered its 4th straight EPS beat (Q1 adjusted EPS $1.78 vs $1.52), raised 2026 outlook to adjusted sales of $92.5B–$93.5B and EPS $6.70–$6.90, and reported FCF +65% to $1.31B, though execution and regulatory/tariff overhangs remain.

Analysis

The real market issue is not whether defense demand is strong; it is where the incremental economics accrue. Backlog and framework agreements are a tailwind for revenue visibility, but the first beneficiaries are the programs with the highest mix of missiles, sensors, and sustainment — where pricing power is better and lead times force customers to commit — while legacy fixed-price work and low-tier suppliers are more exposed to cost overruns, labor scarcity, and working-capital drag. That creates a subtle winner/loser split inside the sector: primes with cleaner execution and higher mix can re-rate, but names carrying heavy production ramps may look better on sales than on cash.

The next 1-3 months are mostly about guide maintenance and appropriation mechanics, not headline geopolitics. If FY2027 funding moves on schedule, the first visible upside should be in bookings and backlog quality; the second-order impact is margin normalization only if plants can convert backlog without another round of unfavorable EACs or inventory build. The biggest falsifier is a funding delay or continuing-resolution environment that pushes awards rightward and leaves primes funding growth ahead of customer cash, which would keep free cash flow under pressure even as EPS looks stable.

Contrarian takeaway: the sector is not uniformly cheap despite the favorable backdrop. RTX’s multiple already prices in a lot of execution, so any unresolved operational or legal overhang can cap upside, while NOC looks like the cleaner value/reversion setup if its operating leverage holds. LMT is the best long-duration franchise but still needs proof that higher-rate missile production translates into cash, not just backlog; until then, the trade is better expressed as relative value than outright beta.

Key Decisions for Investors

• Long NOC on a 3-6 month horizon; add on weakness if the market over-discounts near-term cash flow noise. Thesis breaks if free cash flow stays materially negative through the next two quarters or if B-21/Sentinel execution slips again.
• Pair trade: long NOC / short RTX over the next 1-3 months. The spread should work if investors continue to pay up for RTX growth while underestimating NOC margin recovery; exit if RTX resolves its overhangs or NOC booking momentum stalls.
• Avoid chasing LMT after budget headlines; use it as a conditional buy only if the next quarter shows positive free cash flow and stable segment margins. Until then, it is a backlog story, not yet a cash-conversion story.
• For diversified exposure, prefer a sector basket like ITA/XAR on pullbacks rather than single-name beta if you want the defense spending theme without execution risk in any one prime.
• Set a watch item for FY2027 appropriations and any continuing-resolution risk; if funding slips, trim sector longs because the market will likely have to de-rate backlog visibility into 2027.